1-20 of 62
Rita Nanda
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 766: Genomic and transcriptomic comparison between breast cancers from patients of African and European genetically determined ancestries demonstrates potential for ancestry specific biomarker-informed therapies

Minoru Miyashita, Joshua S. Bell, Ezgi Karaesmen, Brooke Rhead, Stephane Wenric, Kristiyana Kaneva, Francisco M. De La Vega, Yonglan Zheng, Toshio Yoshimatsu, Galina Khramtsova, Elisabeth Sveen, Fang Liu, Fangyuan Zhao, Frederick Howard, Nora T. Jaskowiak, Rita Nanda, Dezheng Huo, Olufunmilayo I. Olopade
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 766.
DOI: https://doi.org/10.1158/1538-7445.AM2022-766
Published: 15 June 2022
View article
Journal Articles

Abstract LB111: Comparison of the predictive and prognostic significance of circulating tumor DNA in patients with high risk HER2-negative breast cancer receiving neoadjuvant chemotherapy

Mark Jesus Mendoza Magbanua, Lamorna Brown Swigart, Derrick Renner, Svetlana Shchegrova, Gillian L. Hirst, Christina Yau, Denise M. Wolf, Hsin-Ta Wu, Ekaterina Kalashnikova, Amy L. Delson, A. Jo Chien, Debu Tripathy, Smita Asare, Raheleh Salari, Angel Rodriguez, Bernhard Zimmermann, Himanshu Sethi, Alexey Aleshin, Paul Billings, Rita Nanda, Hope S. Rugo, Laura J. Esserman, Minetta C. Liu, Angela DeMichele, Laura van 't Veer
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): LB111.
DOI: https://doi.org/10.1158/1538-7445.AM2022-LB111
Published: 15 June 2022
View article
Journal Articles

Abstract P5-13-34: A multi-modal biomarker of immunotherapy response

JR Pfeiffer, Joseph R. Peterson, Frederick Howard, Tyler M. Earnest, Tushar Pandey, Gong He, Rita Nanda
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P5-13-34.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P5-13-34
Published: 15 February 2022
View article
Journal Articles

Abstract PD10-07: Chemokine12 (CK12) tertiary lymphoid gene expression signature as a predictor of response in 3 immunotherapy arms of the neoadjuvant ISPY 2 TRIAL - pembrolizumab with and without SD101, and durvalumab combined with olaparib - and in 9 other arms of the trial including platinum-based and dual-anti-HER2 therapies

Hatem Soliman, Denise Wolf, Jo Chien, Christina Yau, Michael Campbell, Mark Magbanua, Ruixiao Lu, Nicholas O'Grady, Lamorna Brown-Swigart, Gillian Hirst, Beverly Parker, Laura Sit, Smita Asare, Doug Yee, Angie DeMichele, Rita Nanda, Lajos Pusztai, Don Berry, Laura Esserman, Laura Van't Veer
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): PD10-07.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-PD10-07
Published: 15 February 2022
View article
Journal Articles

Abstract P5-16-07: Assessment of sacituzumab govitecan (SG) in Black patients (pts) from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC)

Lisa A. Carey, Amelia Zelnak, Hope S. Rugo, Florence Dalenc, Rita Nanda, Michael Danso, Mahasti Saghatchian, Kevin Kalinsky, Nelly Firmin, Manuel Ruiz-Borrego, Anne Favret, Jun Sun, Lee Schwartzberg, Christie Hilton, Coral Omene, Robyn Young, Sara A. Hurvitz, Eliza Harting, See Phan, Aditya Bardia
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P5-16-07.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P5-16-07
Published: 15 February 2022
View article
Journal Articles

Abstract OT1-18-08: Randomized phase II trial of pembrolizumab/carboplatin vs. carboplatin alone for breast cancer with chest wall recurrence: TBCRC044

Neelima Vidula, Rita Nanda, Kathy Miller, Leisha Emens, Vandana Abramson, Ben Park, Minetta C. Liu, Andrei Goga, Hope Rugo
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): OT1-18-08.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-OT1-18-08
Published: 15 February 2022
View article
Journal Articles

Abstract OT2-01-03: Trial in progress: Phase 2 study of intratumoral plasmid interleukin-12 (tavokinogene telseplasmid; TAVO™) plus electroporation in combination with pembrolizumab with or without chemotherapy in patients with inoperable locally advanced or metastatic triple-negative breast cancer (KEYNOTE-890/OMS-I141)

Melinda Telli, Bianca Devitt, Katharine Cuff, Shaveta Vinayak, Rita Nanda, Alberto J. Montero, Rina Hui, David A. Canton, Christopher Twitty, Sunny Xie, Donna Bannavong, Bridget O'Keeffe, Sandra Aung, Rohit Joshi
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): OT2-01-03.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-OT2-01-03
Published: 15 February 2022
View article
Journal Articles

Abstract P1-08-21: Assessing the impact of treatment interruptions during neoadjuvant therapy in early stage breast cancer

Tushar Pandey, John R Pfeiffer, Eduardo Braun, Hiroyuki Abe, Frederick Howard, Gong He, Alexander T Pearson, Rita Nanda
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P1-08-21.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P1-08-21
Published: 15 February 2022
View article
Journal Articles

Abstract PD9-02: Peripheral immune subsets and circulating tumor DNA (ctDNA) in patients (pts) with residual triple negative breast cancer (TNBC) treated with adjuvant immunotherapy and/or chemotherapy (chemo): The OXEL study

Filipa Lynce, Candace Mainor, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Ute Feger, Renee Donahue, Nicole Toney, Caroline Jochems, Jeffrey Schlom, Christopher Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie Collins, Asma A Dilawari, Ami Chitalia, Shruti Tiwari, Raquel Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Sandra M Swain, Heather A. Parsons, Paula Pohlmann, Claudine Isaacs
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): PD9-02.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-PD9-02
Published: 15 February 2022
View article
Journal Articles

Abstract PD9-10: BRE12-158: A post-neoadjuvant, randomized phase 2 trial of personalized therapy vs. treatment of physician’s choice for patients with residual triple negative breast cancer

Bryan P Schneider, Guanglong Jiang, Tarah J Ballinger, Fei Shen, Christopher Chitambar, Rita Nanda, Carla Falkson, Filipa C Lynce, Christopher Gallagher, Claudine Isaacs, Marcelo Blaya, Elisavet Paplomata, Radhika Walling, Karen Daily, Reshma Mahtani, Michael A Thompson, Robert Graham, Maureen E Cooper, Dean C Pavlick, Lee A Albacker, Jeffery Gregg, Jeffery P Solzak, Yu-Hsiang Chen, Casey L Bales, Erica Cantor, Bradley A Hancock, Nawal Kassem, Paul Helft, Bert O'Neil, Anna Maria Storniolo, Sunil Badve, Kathy D Miller, Milan Radovich
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): PD9-10.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-PD9-10
Published: 15 February 2022
View article
Journal Articles

Abstract GS4-02: Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trial

Beverly Kyalwazi, Christina Yau, Olufunmilayo Olopade, A. Jo Chien, Anne Wallace, Andres Forero-Torres, Lajos Pusztai, Erin Ellis, Kathy Albain, Anne Blaes, Barbara Haley, Judy Boughey, Anthony Elias, Amy Clark, Claudine Isaacs, Rita Nanda, Hyo Han, Rachel Yung, Debu Tripathy, Kristen Edmiston, Rebecca Viscusi, Donald Northfelt, Qamar Khan, Ashish Sanil, Scott Berry, Smita Asare, Amy Wilson, Gillian Hirst, Nola Hylton, Michelle Melisko, Jane Perlmutter, Hope Rugo, Fraser Symmans, Laura van ‘t Veer, Donald Berry, Laura Esserman
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): GS4-02.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-GS4-02
Published: 15 February 2022
View article
Journal Articles

Abstract P3-14-15: The impact of race and age on response to neoadjuvant therapy and long-term outcomes in black and white women with early-stage breast cancer

Elizabeth Terman, Jori Sheade, Fangyuan Zhao, Frederick M. Howard, Nora Jaskowiak, Jennifer Tseng, Olwen Hahn, Gini Fleming, Olufunmilayo I. Olopade, Dezheng Huo, Rita Nanda
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P3-14-15.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P3-14-15
Published: 15 February 2022
View article
Journal Articles

Abstract P4-05-03: Evaluation of the prognostic accuracy of SimBioSys TumorScope in early breast cancer

Frederick M. Howard, Gong He, John R Pfeiffer, Joseph R Peterson, John A. Cole, Alexander T. Pearson, Hiroyuki Abe, Rita Nanda
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P4-05-03.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P4-05-03
Published: 15 February 2022
View article
Journal Articles

Abstract OT-03-03: SGNLVA-001: A phase 1 open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer

Heather C Beckwith, Diana C Medgyesy, Jame Abraham, Rita Nanda, Katherine HR Tkaczuk, Ian E Krop, Lajos Pusztai, Shanu Modi, Monica M Mita, Jennifer M Specht, Sara A Hurvitz, Hyo S Han, Kevin Kalinsky, Sharon Wilks, Joyce O’Shaughnessy, Lowell L Hart, Hope S Rugo, Zahi I Mitri, Phillip M Garfin, Howard A Burris, III
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): OT-03-03.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-OT-03-03
Published: 15 February 2021
View article
Journal Articles

Abstract OT-13-10: Global Phase 3 Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) Following Neoadjuvant or Adjuvant Chemotherapy

Hope Rugo, Louis W.C. Chow, Javier Cortes, Peter A. Fasching, Xu-Bing He, Pei Hsu, Chiun-Sheng Huang, Sung-Bae Kim, Yen-Shen Lu, Michelle Melisko, Rita Nanda, Tillman E Pearce, Priyanka Sharma, Richard Schwab
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): OT-13-10.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-OT-13-10
Published: 15 February 2021
View article
Journal Articles

Abstract OT-13-09: Translational breast cancer research consortium 044 trial: Randomized phase 2 study of pembrolizumab and carboplatin versus carboplatin alone for chest wall recurrence of breast cancer

Neelima Vidula, Rita Nanda, Kathy Miller, Paula Pohlmann, Vandana Abramson, Leisha A. Emens, Ben H. Park, Minetta C. Liu, Andrei Goga, Hope S. Rugo
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): OT-13-09.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-OT-13-09
Published: 15 February 2021
View article
Journal Articles

Abstract OT-33-01: Combination ipatasertib and atezolizumab to prevent recurrence in triple negative breast cancer(TNBC): A phase II single arm trial

Elizabeth Mittendorf, Sara Tolaney, Paul Wileyto, Michelle DeMeo, Hope Rugo, Rita Nanda, Ingrid Mayer, Ben Park, Heather MacArthur, Angela DeMichelle
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): OT-33-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-OT-33-01
Published: 15 February 2021
View article
Journal Articles

Abstract PD14-07: Association between biomarkers and response to pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC): Exploratory analysis from KEYNOTE-086

Sherene Loi, Peter Schmid, Javier Cortes, David W. Cescon, Eric P. Winer, Deborah L. Toppmeyer, Hope S. Rugo, Michelino De Laurentiis, Rita Nanda, Hiroji Iwata, Ahmad Awada, Antoinette R. Tan, Roberto Salgado, Vassiliki Karantza, Petar Jelinic, Anran Wang, Lingkang Huang, Razvan Cristescu, Lakshman Annamalai, Jennifer Yearley, Jennifer Yearley, Sylvia Adams
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PD14-07.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-PD14-07
Published: 15 February 2021
View article
Journal Articles

Abstract PD1-10: Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL

Heather Beckwith, Richard Schwab, Christina Yau, Erica Stringer-Reasor, Shi Wei, A. Jo Chien, Kathy S Albain, Kevin Kalinsky, Anne Wallace, Anthony Elias, Douglas Yee, Amy S Clark, Judy C Boughey, Heather Han, Rita Nanda, Claudine Isaacs, Zahi Mitri, Julie E Lang, Alexandra Thomas, Tara Sanft, Angela DeMichele, Jane Perlmutter, Hope S Rugo, Nola M Hylton, W. Fraser Symmans, Michelle E Melisko, Laura J van't Veer, I-SPY 2 Consortium, Amy Wilson, Smita M Asare, Ashish Sanil, Donald A Berry, Laura J Esserman
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PD1-10.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-PD1-10
Published: 15 February 2021
View article
Journal Articles

Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

Hope Rugo, Antonio Llombart-Cussac, Fabrice Andre, Mark E. Robson, Shigehira Saji, Nadia Harbeck, Peter Schmid, David Cescon, Jin Seok Ahn, Rita Nanda, Li Fan, Jaime Alberto Mejia, Vassiliki Karantza, Aditya Bardia
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): OT-30-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-OT-30-01
Published: 15 February 2021
View article